The appointment of Rabier is intended to help Sanner maximize these expanded capabilities by developing new markets, strengthening relationships with customers, and supporting the company’s international growth strategy.
The move follows Sanner’s acquisition of Springboard in January 2024 and reflects the company’s goal of building a seamless, end-to-end CDMO platform spanning medical technology, pharmaceuticals, and biotechnology.
The new CFO succeeds Henrik Bøggild, who left the company after three and a half years to pursue another professional opportunity.
The device collects saliva-free exhaled breath condensate from the distal lung while minimizing contamination from the mouth, upper airways, and environment, and it integrates into standard diagnostic workflows.